The representative Korean probiotics brand ‘DUOLAC’ participated in ‘Vitafoods Asia 2024’ held in Bangkok, Thailand. Cell Biotech plans to participate in this exhibition with a single booth to promote Korean probiotics and further expand exports in the Asian market.
Vitafoods Asia 2024 will be held for three days from the 18th to the 20th at the Queen Sirikit National Convention Center (QSNCC) in Bangkok. It is the largest health functional food exhibition in Asia, with over 600 companies from 70 countries around the world setting up booths and over 10,000 people attending.
According to Cell Biotech, the main trends at this exhibition were products that exclude unnecessary additives and use only pure raw materials, and personalized solutions using AI technology. The popularity of ‘probiotics’, which are attracting attention for their various roles beyond intestinal health, remained high. About 20% of the seminars dealt with the topic of probiotics, and probiotics products with specific functions received great attention.
As a leading Korean probiotics company, Cell Biotech has consistently participated in international health functional food fairs such as Vitafood Europe and China HNC, and contributed to raising the status of Korean probiotics. It has continued to compete and exchange with companies around the world and introduced the unique technology of CBT probiotics, such as the world patented ‘dual coating’. Accordingly, Duolac has been recognized for its safety and excellence and is exported to 55 countries around the world, ranking first in global exports for 11 consecutive years. In particular, it has been recognized in Denmark and has ranked second in market share in Denmark.
At this expo, Cell Biotech set up a separate booth and actively promoted the excellence, technology, research results, and infrastructure of Korean probiotics centered around the Duolac brand. In particular, the world’s highest level of probiotics technology, such as the world’s most listings of the ‘US FDA GRAS’, the highest level of safety raw material recognition system, and the approval of the clinical phase 1 of ‘PP-P8’, an innovative new drug for colon cancer using probiotics, has attracted the attention of the world.
An official from Cell Biotech said, “This Vitafood Asia 2024 was an important time for Duolac, Korea’s leading probiotic, to strengthen existing partnerships and further expand exports in the Asian market,” adding, “We will continue to focus more on continuous research and development and technological advancement to lead the global probiotic market and enhance the competitiveness of K-probiotics.”